FIGURE 2. Effects of flutamide treatment on NF-kappaB DNA binding activity in the liver at 2 hours after sham operation or trauma-hemorrhage. A, NF-kappaB DNA binding activity. Lane 1, negative (probe only); lanes 2, 3, sham; lanes 4, 5, sham + flutamide; lanes 6, 7, T-H; lanes 8, 9, T-H + flutamide; lane 10, competitive assay using 100 times higher concentration of excessive probe with nuclear extract from T-H group. B, NF-kappaB DNA binding activity. Lane 1, negative (probe only); lane 2, sham; lane 3, T-H; lane 4, T-H + flutamide; lanes 5, 6, T-H + ICI 182,780; lanes 7, 8, T-H + flutamide + ICI 182,780; lane 9, competitive assay using 100 times higher concentration of excessive probe with nuclear extract from T-H group. C, The index of NF-kappaB DNA binding activity in the liver. Data are mean ± SEM (n = 3–5 animals/group). *P < 0.05 versus sham. †P < 0.05 versus T-H. #P < 0.05 versus corresponding group without ICI 182,780. T-H, trauma-hemorrhage; Veh, vehicle treatment; FL, flutamide treatment; ICI, ICI 182,780 treatment; C, competitive assay.